Drug class

Beta-Blockers (Systemic)

Beta-blockers (systemic) are a therapeutic drug class comprising orally or parenterally administered beta-adrenergic receptor antagonists that competitively inhibit endogenous catecholamines throughout the body. Read more about Beta-Blockers (Systemic)

386 drugs in this class 143 manufacturers

Advertisement

Drugs in Beta-Blockers (Systemic)

Showing 145–153 of 386 drugs

PROPRANOLOL HCL

BETA-BLOCKERS (SYSTEMIC) · PHEOCHROMOCYTOMA ADJUNCT THERAPY ·+7
PHARMACEU ASSOC

LABETALOL HCL

ALPHA-BLOCKERS · HYPERTENSION
Baxter Healthcare Company

ATENOLOL

BETA-BLOCKERS (SYSTEMIC) · HYPERTENSION ·+2
Major Pharamceuticals

NADOLOL

BETA-BLOCKERS (SYSTEMIC) · HYPERTENSION ·+1
Major Pharamceuticals

SOTALOL (sotalol HCl)

ANTIARRHYTHMIC - CLASS III · LIFE-THREATENING VENTRICULAR TACHYCARDIA ·+2
Major Pharamceuticals
Filter & compare in the drug finder → Opens the drug finder with Beta-Blockers (Systemic) preselected. Add indication or manufacturer filters there.

About Beta-Blockers (Systemic).

Beta-blockers (systemic) are a therapeutic drug class comprising orally or parenterally administered beta-adrenergic receptor antagonists that competitively inhibit endogenous catecholamines throughout the body.

By blocking cardiac beta-1 and peripheral beta-2 receptors, these medications exert negative inotropic and chronotropic effects, slowing the heart rate, decreasing myocardial contractility, and lowering systemic arterial blood pressure.

They are primarily indicated across cardiovascular medicine for the management of hypertension, angina pectoris, cardiac arrhythmias, myocardial infarction, and chronic heart failure with reduced ejection fraction.

Additionally, systemic beta-blockers play key therapeutic roles in non-cardiovascular conditions, including migraine prophylaxis, essential tremor, and the symptomatic management of thyrotoxicosis.